An interventional study of Telemedicine in Type 2 Diabetes, Poor Glycemic Control and Medication Adherence, sponsored by Bispebjerg Hospital. Completed at 1 site in Denmark. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-19.
Sponsored by Bispebjerg Hospital · Not applicable, Interventional, and Supportive care
The aim of the study is to investigate the effect of telemedicine among the group of type-2-diabetics who, despite rehabilitation, remain poorly regulated. To describe the patients with regards to vulnerability and social resources and to determine wich groups benefit the most from telemedicine.
Type-2-diabetes is a growing healthcare problem. Both because of the increasing amount of patients and because of the complications of diabetes.
Non-pharmacological treatment is considered fundamental in the treatment of patients with type-2-diabetes.
In the Community of Copenhagen, all patients diagnosed with diabetes receive rehabilitation. The rehabilitation consists of counseling with regards to nutrition, physical activity, smoking cessation and education about diabetes.
Some patients however, remain poorly regulated despite rehabilitation as well as pharmacological treatment.
A total number of 165 patients will be randomized to intervention group or standard care.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 165 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Bispebjerg Hospital is the lead sponsor of 281 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Monthly video consultations with a nurse as add-on to standard treatment.
Behavioral: Telemedicine
Standard diabetes control at a Diabetes Clinic or GP
Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices. Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks.
Changes in HbA1c
Time frame: Baseline, 16 weeks, 32 weeks, 6 months after intervention
Fasting total cholesterol, LDL, HDL, triglycerides
Time frame: Baseline, 32 weeks
Beta-cell function test (HOMA)
Time frame: Baseline, 32 weeks
Weight
Time frame: Baseline, 32 weeks
Bloodpressure
Time frame: Baseline, 32 weeks
Physical activity
Time frame: Baseline, 32 weeks
Change in quality of life
Time frame: Baseline, 32 weeks
Waist circumference
Time frame: Baseline, 32 weeks
Hip circumference
Time frame: Baseline, 32 weeks
Body mass index
Time frame: Baseline, 32 weeks
Use of medication
Time frame: Baseline, 32 weeks
Number of hospital admissions
Time frame: 32 weeks
Number of visits at the emergency
Time frame: 32 weeks
Number of visits at the outpatient department
Time frame: 32 weeks
Number of visits at GP
Time frame: 32-weeks
Plan to share: No
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bispebjerg Hospital